timi天美传孟若羽

　　基于临床实践与科研紧密结合的模式，专注抗血栓领域，进行创新药物评价与体外诊断产物研究。参与完成首个国产化贬滨罢试剂盒的研发与成果转化，该试剂盒于2023年获得北京市创新医疗器械认证、2024年获得医疗器械注册证。主持了国自然青年基金、北京市首度卫生发展专项基金、黑龙江省揭榜挂帅科技攻关项目子课题、中央高水平研究项目（院内跨学科交叉项目、希望之星、转化孵育项目）、北大医学青年培育项目、中国药学会施维雅青年医院药学创新研究项目和中华医学会临床药学分会科研基金项目等多项科研项目。先后获得2022年北京医学会第叁届首都医学创新与转化项目展示与科技评价活动优胜奖、北大医学首届创新转化大赛医疗器械组优秀项目奖、2021年北京市卫生健康委员会第叁届首都转化医学创新大赛优秀项目奖。

北京市医药卫生科技创新成果转化专家库成员，中国药理学会临床药理专业委员会委员，中国药理学会定量药理学专业委员会委员，中国药理学会国际科技组织后备人才，中关村生物医药创新协会第五届理事会理事，《抗感染药学》青年编委。

一作或者并列一作文章发表情况（时间倒序）：（请根据要求能放几篇，选择近些年的即可）

[1] Liu Z, Xie Q, Zhao X, Tan Y, Wang W, Cao Y, Wei X, Mu G, Zhang H, Zhou S, Wang X, Cao Y, Li X, Chen S, Cao D, Cui Y, Xiang Q. The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study. Clin Ther. 2024 Apr;46(4):313-321.

[2] Liu Z#, Li L#, Zhang H, Pang X, Qiu Z, Xiang Q, Cui Y. Platelet factor 4(PF4) and its multiple roles in diseases. Blood Rev. 2024 Mar;64:101155.

[3] Liu ZY, Sun MX, Hua MQ, Zhang HX, Mu GY, Zhou S, Wang Z, Xiang Q, Cui YM. New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF. Front Immunol. 2023 Feb 28;14:1098665. 

[4] Liu Z#, Liu Y#, Mu G, Zhang H, Zhou S, Wang Z, Xie Q, Wang Z, Guo N, Huang J, Guo L, Huang Y, Li J, Yang G, Yuan D, Song H, Jiang J, Xiang Q, Cui Y. Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome. Clin Pharmacokinet. 2023 Mar;62(3):435-447. 

[5] Liu Z, Mu G, Xie Q, Zhang H, Jiang J, Xiang Q, Cui Y. Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study. Front Cardiovasc Med. 2022 Jul 22;9:894888.

[6] Xiang Q#, Liu Z#, Mu G, Xie Q, Zhang H, Zhou S, Wang Z, Guo N, Huang J, Jiang J, Li J, Yang G, Cui Y. Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects. Clin Drug Investig. 2022 May;42(5):447-458. 

[7] Liu ZY, Zhang HX, Ma LY, Mu GY, Xie QF, Zhou S, Wang ZN, Wang Z, Hu K, Xiang Q, Cui YM. Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies. BMC Cardiovasc Disord. 2022 Mar 14;22(1):105.

[8] Liu Z#, Ma L#, Zhang H, Mu G, Xie Q, Zhou S, Wang Z, Wang Z, Hu K, Gong Y, Jiang J, Xiang Q, Cui Y. Comparison of non-vitamin K antagonist oral anticoagulants on bleeding and thrombosis. J Clin Pharm Ther. 2021 Dec;46(6):1729-1742.

[9]  Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study. Am J Cardiovasc Drugs. 2021 Nov;21(6):669-679.

[10] Liu Z#, Xie Q#, Xiang Q, Zhang H, Mu G, Zhao Z, Hu T, Wu T, Wang N, Zhang J, Qian Y, Zhou S, Wang Z, Jiang J, Zhang Y, Song H, Cui Y. Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study. Cardiovasc Diagn Ther. 2020 Oct;10(5):1293-1302. 

[11] Liu Z, Zhang H, Xie Q, Mu G, Zhou S, Wang Z, Wang Z, Jiang J, Xiang Q, Cui Y. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Ther. 2020 Oct;42(10):2066-2081. 

[12] Zhang H#, Liu Z#, Mu G, Wang Z, Zhou S, Xie Q, Ma L, Wang Z, Hu K, Gong Y, Jiang J, Xiang Q, Cui Y. Diagnostic performance of coagulation indices for direct oral anticoagulant concentration. Thromb Res. 2020 Nov;195:171-179.

[13] Xiang Q#, Liu Z#, Yu Y, Zhang H, Xie Q, Mu G, Zhang J, Cen X, Cui Y. Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. BMC Pharmacol Toxicol. 2020 Jun 5;21(1):43. 

[14] Liu Z, Xiang Q, Mu G, Xie Q, Zhou S, Wang Z, Chen S, Hu K, Gong Y, Jiang J, Cui Y. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis. Platelets. 2020;31(1):3-14. 

[15] Liu Z, Xiang Q, Mu G, Xie Q, Zhou S, Wang Z, Chen S, Hu K, Gong Y, Jiang J, Cui Y. Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019 Apr 2;8(7):e010889.

[16] Liu Z, Xiang Q, Zhao X, Wang Z, Mu G, Xie Q, Zhou S, Chen S, Hu K, Xu J, Ma L, Cui Y. Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics. Thromb Res. 2019 Jan;173:27-34.